<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04196608</url>
  </required_header>
  <id_info>
    <org_study_id>MICRO.HGUGM.2019-008</org_study_id>
    <nct_id>NCT04196608</nct_id>
  </id_info>
  <brief_title>In Vitro Activity of Ceftolozane/Tazobactam and Imipenem/Relebactam in Clinical Isolates of Pseudomonas Aeruginosa and Enterobacterales Collected From Hematology and Oncology Patients</brief_title>
  <acronym>ACTHEON</acronym>
  <official_title>In Vitro Activity of Ceftolozane/Tazobactam and Imipenem/Relebactam in Clinical Isolates of Pseudomonas Aeruginosa and Enterobacterales Collected From Hematology and Oncology Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emilio Bouza</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital General Universitario Gregorio Marañon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the ACTHEON Study is to evaluate the in vitro activity of
      ceftolozane-tazobactam, imipenem-relebactam and comparator agents (amoxicillin- clavulanate,
      piperacillin-tazobactam, ceftazidime, cefotaxime, cefepime, imipenem, meropenem, levofloxacin
      and amikacin; see list more details on page 7) against clinical isolates of P. aeruginosa and
      Enterobacterales prospectively collected from hematology and oncology patients with
      complicated intra-abdominal infections (cIAIs), complicated urinary infections (cUTIs), lower
      respiratory tract infections (LRTIs), and blood stream infections (BSIs) from 15
      participating centers in Spain
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2019</start_date>
  <completion_date type="Anticipated">September 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Summary MIC and its distributions as susceptible, intermediate and resistant</measure>
    <time_frame>31 october 2020</time_frame>
    <description>Summary of MIC data, distribution presented as the cumulative MIC frequency, MIC50, MIC90, and MIC range for each antimicrobial and species.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Summary of percentages of isolates</measure>
    <time_frame>31 october 2020</time_frame>
    <description>Summary of percentages of isolates interpreted as susceptible, intermediate and resistant isolates according to CLSI and EUCAST guidelines, when available, for each species and for the total study isolates.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1005</enrollment>
  <condition>Ceftolozane/Tazobactam</condition>
  <condition>Imipenem/Relebactam</condition>
  <condition>Hematology and Oncology</condition>
  <arm_group>
    <arm_group_label>P. aeruginosa isolates</arm_group_label>
    <description>All isolates will be sent to the Central Laboratory, where identification will be confirmed by MALDI-TOF and susceptibility testing against ceftolozane/tazobactam, imipenem- relebactam and comparative agents will be performed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enterobacterales isolates</arm_group_label>
    <description>All isolates will be sent to the Central Laboratory, where identification will be confirmed by MALDI-TOF and susceptibility testing against ceftolozane/tazobactam, imipenem- relebactam and comparative agents will be performed</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ceftolozane/tazobactam</intervention_name>
    <description>Minimum inhibitory concentrations (MICs) will be determined by the standard broth microdilution method (standard ISO method 20776-1:2006) using dry-form Sensititre panels (Thermo Fisher Scientific, Denmark) and will be interpreted according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) and the Clinical and Laboratory Standards Institute (CLSI) criteria</description>
    <arm_group_label>Enterobacterales isolates</arm_group_label>
    <arm_group_label>P. aeruginosa isolates</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>imipenem- relebactam</intervention_name>
    <description>Minimum inhibitory concentrations (MICs) will be determined by the standard broth microdilution method (standard ISO method 20776-1:2006) using dry-form Sensititre panels (Thermo Fisher Scientific, Denmark) and will be interpreted according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) and the Clinical and Laboratory Standards Institute (CLSI) criteria</description>
    <arm_group_label>Enterobacterales isolates</arm_group_label>
    <arm_group_label>P. aeruginosa isolates</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participating laboratories will prospectively collect the first 1,005 clinical isolates
        (510 P. aeruginosa isolates and 495 Enterobacterales isolates) starting in a preestablished
        date from patients with cIAIs, cUTIs, LRTIs, or BSIs
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  P. aeruginosa isolates

          -  Enterobacterales isolates

        Exclusion Criteria:

          -  Non P. aeruginosa isolates

          -  Non Enterobacterales isolates
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Emilia Cercenado</last_name>
    <phone>+34-915868459</phone>
    <email>emilia.cercenado@salud.madrid.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>HG Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emilia Cercenado</last_name>
      <phone>+34-915868459</phone>
      <email>emilia.cercenado@salud.madrid.org</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 3, 2019</study_first_submitted>
  <study_first_submitted_qc>December 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 12, 2019</study_first_posted>
  <last_update_submitted>December 10, 2019</last_update_submitted>
  <last_update_submitted_qc>December 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital General Universitario Gregorio Marañon</investigator_affiliation>
    <investigator_full_name>Emilio Bouza</investigator_full_name>
    <investigator_title>Phd, MD Senior Assesor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tazobactam</mesh_term>
    <mesh_term>Imipenem</mesh_term>
    <mesh_term>Ceftolozane</mesh_term>
    <mesh_term>Ceftolozane, tazobactam drug combination</mesh_term>
    <mesh_term>MK-7655</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Fiveteen laboratories (Participating laboratories) will participate under the direction of Dr. E. Cercenado, Department of Microbiology and Infectious Diseases, Gregorio Marañón University Hospital, Madrid, Spain (Central laboratory), on behalf of the GEIRAS-SEIMC (Group for the Study of Healthcare-Related Infections of the Spanish Society for Infectious Diseases and Clinical Microbiology).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

